Eli Lilly one of the world's leading pharmaceutical groups, could regain its upward trend after having run out of steam.

The fundamentals support the stock with a gradual upward revision of earnings per share by analysts. Yet, the Thomson Reuters consensus expect sales to grow for the fiscal year at 22706 M USD against 24287 M USD for the previous year.

Technically, the uptrend in the medium and long term should protect the stock of a major downtrend. In the short term, a decline could lead the share to the USD 42 support. Therefore, a technical rebound will fix an objective near to the USD 44.50 short-term resistance.

Consequently, we expect a decline toward USD 42. The most active investors can buy the share in this area and target a return toward USD 44.50. A stop loss can be placed under the USD 41.5 support.